Personalised Cancer Medicine Flashcards 2022

Indications determined by the organ of origin
Colorectal Cancer
Colorectal Cancer



Currently not recommended
  • Microsatellite Instability study*
  • BRAF
  • DPD
  • NTRK**
  • HER2***
  • Inmunoscore
  • CMS classification
  • MET
  • EGFR
  • FGFR
  • PI3K
* by IHQ (MLH1, PMS2, MSH2 and MSH6) o genetic study (BAT25 and BAT26, D2S123, D5S346 and D17S250).
** in tumors with microsatellite instability, MIG1 hypermetilation and RAS wild type (IHQ + FISH, NGS, RT-PCR, NanoString)
***(IHQ or FISH or NGS) en RAS y BRAF WT
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.


1. García-Alfonso P, García-Carbonero R, García-Foncillas J, et al. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2020 Nov;22(11):1976-1991. doi: 10.1007/s12094-020-02357-z.

2. Kolenčík D, Shishido SN, Pitule P, et al. Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. Cancers (Basel). 2020 May 27;12(6):1376. doi: 10.3390/cancers12061376.

3. Garrido P, Hladun R, de Álava E, et al. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. Clin Transl Oncol. 2021 Feb 23. doi: 0.1007/s12094-021-02558-0